Drug class
Antineoplastic - Protein Methyltransferase (PMT) Inhibitors
Antineoplastic protein methyltransferase (PMT) inhibitors are targeted epigenetic anticancer agents designed to disrupt aberrant post-translational methylation of histone and non-histone proteins. Read more about Antineoplastic - Protein Methyltransferase (PMT) Inhibitors
0 drugs in this class 0 manufacturers
Drugs in Antineoplastic - Protein Methyltransferase (PMT) Inhibitors
No drugs are available
This class does not currently contain public drugs.
Antineoplastic protein methyltransferase (PMT) inhibitors are targeted epigenetic anticancer agents designed to disrupt aberrant post-translational methylation of histone and non-histone proteins.
By selectively blocking methyltransferase enzymes—most notably enhancer of zeste homolog 2 (EZH2)—these agents prevent abnormal gene silencing, restore tumor suppressor pathways, and induce malignant cell differentiation or apoptosis.
Clinically, this pharmacologic class is indicated for malignancies characterized by specific epigenetic alterations, such as epithelioid sarcoma and relapsed or refractory follicular lymphoma, with ongoing investigations across hematologic cancers and solid tumors.
-
nih.gov
Antineoplastic protein methyltransferase (PMT) inhibitors are targeted epigenetic anticancer agents designed to disrupt aberrant post-translational methylation of histone and non-histone proteins
-
frontiersin.org
Antineoplastic protein methyltransferase (PMT) inhibitors are targeted epigenetic anticancer agents designed to disrupt aberrant post-translational methylation of histone and non-histone proteins
-
nih.gov
By selectively blocking methyltransferase enzymes—most notably enhancer of zeste homolog 2 (EZH2)—these agents prevent abnormal gene silencing, restore tumor suppressor pathways, and induce malignant cell differentiation or apoptosis
-
royalsocietypublishing.org
By selectively blocking methyltransferase enzymes—most notably enhancer of zeste homolog 2 (EZH2)—these agents prevent abnormal gene silencing, restore tumor suppressor pathways, and induce malignant cell differentiation or apoptosis
-
nih.gov
Clinically, this pharmacologic class is indicated for malignancies characterized by specific epigenetic alterations, such as epithelioid sarcoma and relapsed or refractory follicular lymphoma, with ongoing investigations across hematologic cancers and solid tumors
-
fda.gov
Clinically, this pharmacologic class is indicated for malignancies characterized by specific epigenetic alterations, such as epithelioid sarcoma and relapsed or refractory follicular lymphoma, with ongoing investigations across hematologic cancers and solid tumors
-
moalmanac.org
Clinically, this pharmacologic class is indicated for malignancies characterized by specific epigenetic alterations, such as epithelioid sarcoma and relapsed or refractory follicular lymphoma, with ongoing investigations across hematologic cancers and solid tumors
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.